Please use this identifier to cite or link to this item:
|Title:||Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?|
|Authors:||Forbes, Josephine M|
|Affiliation:||Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia|
Mater Research Institute, The University of Queensland, TRI, Brisbane, Queensland, Australia
Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia
|Citation:||Kidney international 2020; 97(5): 855-857|
|Abstract:||Diabetes affects oxygen availability in the kidney, forcing the renal environment to rapidly and sustainably adapt. Physiological adaptations including activation of hypoxia inducible factor-1α and metabolic reprogramming toward pathways requiring less oxygen to maintain adenosine triphosphate production such as anaerobic glycolysis are impaired in the diabetic kidney. However, this study by Hasegawa et al. demonstrates renoprotection in diabetic kidney disease via the use of the hypoxia inducible factor-1α stabilizer enarodustat, opening a new therapeutic avenue to tackle these metabolic abnormalities.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.